Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Jiankangyuan's anti-influenza drug application for market listing

Published Time:

2024-08-12

On August 12, the CDE website showed that the marketing application for the influenza drug TG-1000 capsules of Health Spring has been accepted.

 

 

This year In April, Health Spring announced that the multicenter Phase III clinical trial of TG-1000 capsules for the treatment of uncomplicated influenza A and B acute infections in patients aged 12 years and older without complications had met its primary endpoint, and stated that it would communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in the near future regarding the marketing application for TG-1000 capsules for the treatment of influenza, to advance the listing process of TG-1000 capsules.

 

TG-1000 is a first-class innovative anti-influenza drug, a novel cap-dependent endonuclease inhibitor, originally developed by Taiji Pharmaceutical and Taiji Bio. Early research data showed that TG-1000 has the characteristics of rapid onset, long viral suppression time, good tolerance, and oral administration unaffected by food, and can effectively inhibit both influenza A and B viruses.

 

In September 2023, Health Spring, as the applicant, and the First Affiliated Hospital of Guangzhou Medical University, as the leading unit, launched a Phase III clinical trial (n=752) of TG-1000 capsules for the treatment of influenza. This study is a multicenter, randomized, double-blind clinical trial, with the primary endpoint being the time to resolution of all influenza symptoms within 15 days of treatment.

 

Preliminary statistical analysis results show that, The median time to resolution of all influenza symptoms in the TG-1000 group and the placebo group were 60.9 hours and 87.9 hours, respectively, meeting the primary efficacy endpoint and showing a statistically significant difference (P<0.0001). In terms of safety, the incidence of adverse events (AEs) in the TG-1000 group was similar to that in the placebo group, with no deaths or drug-related serious adverse reactions.
 


This article is transferred from: Pharmaceutical Cube Info